Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 569-576

  Grabert, Ryan C ^a   Cousens, Leslie P ^a,e   Smith, Janelle A ^c   Olson, Sarah ^d   Gall, Jonathan ^e   Young, Wendy B ^a   Davol, Pamela A ^a   Lum, Lawrence G ^a,b,e  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIBODY; CD3 ANTIGEN; CHROMIUM 51; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OKT 3; PERFORIN; RANTES; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER IMMUNOTHERAPY; CELL CYCLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; PORE FORMING CYTOTOXIC PROTEINS; RANTES; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 31544434016     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2005     Document Type: Article

References (39)

1. Sen M, Wankowski DM, Garlie NK, et al. Use of anti-CD3 × anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu Tumors. J Hematother Stem Cell Res 2001;10:247-60.
2. Davol PA, Smith JA, Kouttab N, Elfenbein GJ, Lum L. Anti-CD3 × anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing SCID-Beige mice. Clin Prostate Cancer 2004;3:112-21.
3. Lum HE, Miller M, Davol PA, Graben RC, Davis JB, Lum LG. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas. Anticancer Res 2005;25:43-52.
4. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol 1995;25:1071-9.
5. Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98-104.
6. Slifka MK, Rodriguez F, Whitton JL. Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells. Nature 1999;401:76-9.
7. Uberti JP, Joshi I, Ueda M, Martilotti F, Sensenbrenner LL, Lum LG. Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC restricted cytotoxicity. Clin Immunol Immunopathol 1994;70:234-40.
8. Ueda M, Joshi ID, Dan M, et al. Preclinical studies for adoptive immunotherapy in bone marrow transplantation: II. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Transplantation 1993;56:351-6.
9. Lyons AB, Parish CR. Determination of Lymphocyte division by flow cytometry. J Immunol Methods 1994;171:131-7.
10. Klinman, DM, Nutman TB. ELISPOT assay to detect cytokine-secreting murine and human cells In: Colligan JE, Kruisbeck A, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology. John Wiley & Sons, Inc.; 1994. p. 6.16.1-6.19.6.
11. McCutcheon M, Wehner N, Wensky A, et al. Asensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997;210:149-66.
12. Kataoka T, Shinohara N, Takayama H, et al. Concanamycin A, a powerful tool for characterization and estimation of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996;156:3678-86.
13. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989;86:1333-7.
14. Lindsten T, June CH, Lebetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989;244:339-43.
15. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dorken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 1997;159:3808-15.
16. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998;8:89-95.
17. Kriangkum J, Xu B, Gervais C, et al. Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma. Hybridoma 2000;19:33-41.
18. Krummel MF, Davis MM. Dynamics of the immunological synapse: finding, establishing and solidifying a connection. Curr Opin Immunol 2002;14:66-74.
19. Lanzavecchia A, Sallusto F. Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol 2001;2:487-92.
20. Levine BL, Bernstein WB, Connors M, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159:5921-30.
21. Bradley MB, Dalton DK, Croft M. A direct role for IFN-γ in regulation of Th1 cells development. J Immunol 1996;157:1350-8.
22. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK. Role of interferon-γ in mediating the antitumor efficacy of interleukin 12. J Immunother 1995;17:71-7.
23. Manetti R, Gerosa F, Giudizi MG, et al. Interleukin 12 induces stable priming for interferon-γ (IFN-γ) production during differentiation of human T helper (Th) cells and transient IFN-γ production in established Th2 cell clones. J Exp Med 1994;179:1273-83.
24. Su HC, Nguyen KB, Salazar-Mather TP, Ruzek MC, Dalod MY, Biron CA. NK cell functions restrain T cell responses during viral infections. Eur J Immunol 2001;31:3048-55.
25. Young HA, Ghosh P, Ye J, et al. Differentiation of the T helper phenotypes by analysis of the methylation state of the IFN-γ gene. J Immunol 1994;153:3603-10.
26. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669-71.
27. Taub DD, Sayers TJ, Carter CR, Ortaldo JR. α and β chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 1995;155:3877-88.
28. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990;128:189-201.
29. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-41.
30. She J, Ruzek MC, Velupillai P, et al. Generation of antigen-specific cytotoxic T lymphocytes and regulation of cytokine production takes place in the absence of CD3zeta. Int Immunol 1999;11:845-57.
31. Ehl S, Hombach J, Aichele P, Hengartner H, Zinkernagel RM. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med 1997;185:1241-51.
32. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2:415-22.
33. Wong P, Pamer EG. Cutting edge: antigen-independent CD8 T cell proliferation. J Immunol 2001;166:5864-8.
34. Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 1999;286:1377-81.
35. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
36. Kishimoto H, Sprent J. Strong TCR ligation without costimulation causes rapid onset of Fas-dependent apoptosis of naive murine CD4+ T cells. J Immunol 1999;63:1817-26.
37. Baumann S, Krueger A, Kirchhoff S, Krammer PH. Regulation of T cell apoptosis during the immune response. Curr Mol Med 2002;2:257-72.
38. Sprent J. Life spans of naive, memory and effector lymphocytes. Curr Opin Immunol 1993;5:433-8.
39. Lum LG, Rathore R, Cummings F, et al. Phase I/II study of treatment of stage IV breast cancer with OKT3 × trastuzumab-armed activated T cells. Clin Breast Cancer 2003;4:212-7.